Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Supply Chain Constraints ‘Will Limit Vascepa Threat’

Dr Reddy’s And Hikma Have Path To Market

Executive Summary

Supply is the million-dollar question for Vascepa ANDA sponsors, with Dr Reddy’s and Hikma receiving a further green light to introduce their generics into the US market.

You may also be interested in...



Amarin Raises Supply Issue Again On US Vascepa Generics

With Hikma having launched the first generic version of Vascepa (icosapent ethyl) in the US last year, Amarin has again raised the issue of ANDA product supply for the complex purified fish oil brand.

Hikma’s Vascepa Launch Strategy ‘Can Cause Market Confusion’

Issues over supply and the use of a skinny label have the potential to take a toll on the market for the fish oil drug icosapent ethyl, one analyst has claimed in the wake of Hikma’s recent generic launch.

Hikma Launches US Vascepa Rival As Amarin Appeal Denied

Hikma has launched its US rival to Vascepa, after the US Court of Appeals for the Federal Circuit refused a request by Amarin for an “en banc” rehearing of key litigation.

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

GB150228

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel